Citius Oncology, Inc. (CTOR)

Market Cap	151.20M
Revenue (ttm)	n/a
Net Income (ttm)	-17.48M
Shares Out	75.60M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	689,795
Open	2.270
Previous Close	2.250
Day's Range	1.880 - 2.270
52-Week Range	1.880 - 4.420
Beta	n/a
Analysts	Strong Buy
Price Target	6.00 (+200.0%)
Earnings Date	n/a

About CTOR

Citius Oncology, Inc. develops a oncology therapies. The company was formerly known as Citius Acquisition Corp. and changed its name to Citius Oncology, Inc. in May 2023. Citius Oncology, Inc. was incorporated in 2021 and is headquartered in United States. The company operates as a subsidiary of Citius Pharmaceuticals, Inc.

• Founded: 2021
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: CTOR

Financial Performance

Financial numbers in USD

Analyst Forecast

According to one analyst, the rating for CTOR stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(200.00% upside)

Analyst Consensus: Strong Buy